Physician profile
Gregory Parks
NPI 1780917997
$1,221.18
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $991 · 2020: $231.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $159.21 | 2019 | |
| Acadia Pharmaceuticals INC | $158.77 | 2019-2020 | |
| Lilly USA, LLC | $155.34 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $138.32 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $127.53 | 2019-2020 | |
| Livanova USA, INC. | $120.71 | 2019 | |
| Emd Serono, INC. | $120.66 | 2019-2020 | |
| Ucb, INC. | $48.03 | 2019 | |
| Genzyme Corporation | $33.70 | 2019-2020 | |
| Kyowa Kirin, INC. | $27.05 | 2020 | |
| Chiesi USA, INC. | $24.87 | 2019 | |
| Abbvie INC. | $17.52 | 2020 | |
| Allergan, INC. | $15.11 | 2020 | |
| Ge Healthcare | $14.71 | 2019 | |
| Supernus Pharmaceuticals, INC. | $12.95 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $12.40 | 2019 | |
| Amgen INC. | $11.90 | 2020 | |
| Adamas Pharmaceuticals, INC. | $11.59 | 2019 | |
| Biogen, INC. | $10.81 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Parks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.